- A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Ki Jeong Jeon, Cheol-Won Choi, Kyung-Su Kim, Wan Jeon
-
J Liver Cancer. 2019;19(1):74-78. Published online March 31, 2019
-
DOI: https://doi.org/10.17998/jlc.19.1.74
-
-
Abstract
PDF
- Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a firstline treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy.
- A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Ki Jeong Jeon, Sang Bu Ahn, Jin-Young Park, Cheol-Won Choi, Kwang-Mo Yang
-
J Liver Cancer. 2017;17(1):88-93. Published online March 31, 2017
-
DOI: https://doi.org/10.17998/jlc.17.1.88
-
-
Abstract
PDF
- Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of
advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under
3 months is far from clinical satisfactory and most patients experience disease progression within
6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment
failure of sorafenib was not established and there were no clear guidelines for salvage treatment
modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent
can be relatively effective and safe strategy that achieves promising rates of local and systemic
control in advanced HCC patients. Based on above suggestions, we herein offer our experience
of a case achieved complete remission by combination therapy of sorafenib and tegafur in the
patient with progressed disease after sorafenib therapy.
- A Case of Achieving Complete Remission with Stereotactic Body Radiation Therapy in Patients with Hepatocellular Carcinoma with Macrovascular Invasion after Repeated Transarerial Chemoembolization
-
Sang Youn Hwang, Seon-Mi Lee, Jong Woo Im, Ki Jeong Jeon, Sang Bu Ahn, Eun Kyeong Ji, Jin-Young Park, Cheol-Won Choi Choi, Gwang-Mo Yang
-
J Liver Cancer. 2016;16(2):123-128. Published online September 30, 2016
-
DOI: https://doi.org/10.17998/jlc.16.2.123
-
-
Abstract
PDF
- Transarterial chemoembolization (TACE) is the worldwide procedure performed for patients
with various stage hepatoceullar carcinoma (HCC), but is not yet considered as curative
treatment because of relatively high local recurrence rate. Moreover, many clinicians
frequently experience treatment failure (incomplete necrosis or stage progression etc.) after
repeated TACE, but no clear guidelines have been recommended about salvage treatment
modalities for this situation. Recently, studies for combination of radiation therapy and TACE
for HCC with TACE refractoriness have been tried and reported better therapeutic efficacy.
Based on above suggestions, we herein offer our experience of a patient with macrovascular
invasion developed after repeated TACE that achieve complete remission by stereotactic
body radiation therapy. Further study, maybe regarding a combination of locoregional and
systemic therapy, is necessary on how to manage HCC patients with TACE refractoriness.
- A Case of Achieving Complete Remission with Combination of Stereotactic Body Radiation Therapy and Transarterial Chemoemoblization in Patients with 4.8 cm Sized Infiltrative Hepatocellular Carcinoma with Arteriovenous Shunt
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Joon Suk Kim, Ki Jeong Jeon, Sang Bu Ahn, Eun Kyeong Ji, Hyun-Cheol Kang, Cheol-Won Chol, Gwang-Mo Yang
-
J Liver Cancer. 2015;15(1):64-69. Published online March 31, 2015
-
DOI: https://doi.org/10.17998/jlc.15.1.64
-
-
Abstract
PDF
- Infiltrative hepatocellular carcinoma (HCC) patients have a poor prognosis because most
patients present with advanced disease. Although tumor size is small, ablation therapy
is difficult because it is difficult to delineate tumor boundary and tumor often combined
vascular invasion. Therefore many clinicians still try locoregional therapy (LRT) such as
transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT
and sorafenib in this situation. Stereotactic body radiation therapy (SBRT) is new technology
providing very highly conformal ablative radiation dose and is expected to salvage modality
for HCC showed incomplete response of TACE due to combined arteriovenous (AV) shunts.
Based on above suggestions, we herein offer our experience of a complete remission of tumor
by combination of SBRT and TACE in a patient with infiltrative HCC. Further study, maybe
regarding a combination of locoregional and systemic therapy is necessary on how to manage
infiltrative HCC with AV shunts.
- A Case of Achieving Partial Remission with Combination of Radiation Therapy and Sorafenib inChild-Pugh Class B Patients with Hepatocellular Carcinoma with Main Portal Vein Invasion and Lymph Node Metastasis
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Joon Suk Kim, Sang Bu Ahn, Eun Kyeong Ji, Hyun-Cheol Kang, Cheol-Won Choi, Gwang-Mo Yang
-
J Liver Cancer. 2014;14(2):120-126. Published online September 30, 2014
-
DOI: https://doi.org/10.17998/jlc.14.2.120
-
-
Abstract
PDF
- Reserved liver function is one of the most important determinants of survivial in advanced
hepatocellular carcinoma (HCC). Especially in cirrhotic patient with decompensated liver
function, sorafenib for HCC with main portal vein invasion have limited efficacy and survival
benefit. Therefore many clinicians or centers still try locoregional therapy (LRT) such as
transarterial chemoembolization (TACE), radiation therapy (RT), or combination with LRT
and sorafenib in this situation. However this multidisciplinary approach may increase
treatment related toxicity such as liver failure, etc. Recently, studies for combination of RT
and sorafenib for HCC with portal vein invasion have been tried and reported not only better
therapeutic efficacy, but also more hepatic toxicity.Based on above suggestions, we herein
offer our experience of a patient that although achieved survival gain via partial remission
of intrahepatic tumor and main portal vein thrombosis and metastatic lymph node by
combination therapy of RT and sorafenib, finally expired due to hepatictoxicity. Further study,
maybe regarding a combination of locoregional and systemic therapy, is necessary on how to
manage decompenstated cirrhotic patients with HCC with main portal vein invasion. (J Liver
Cancer 2014;14:120-126)
- A Case of Hypovascular Hepatocellular Carcinoma Invading Bile Duct with Partial Remission with Combination Therapy of Transarterial Chemoembolization and Stereotactic Body Radiation Therapy and Sorafenib
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Joon Suk Kim, Sang Bu Ahn, Eun Kyeong Ji, Chul Won Choi, Gwang-Mo Yang
-
Journal of the Korean Liver Cancer Study Group. 2013;13(2):178-184. Published online September 30, 2013
-
DOI: https://doi.org/10.17998/jlc.13.2.178
-
-
Abstract
PDF
- Hepatocellular carcinoma (HCC) patients with bile duct invasion have a poor prognosis because many do not receive effective treatment. Surgical resection is thought to be only option of curative treatment, increasing chance of survival, but it is possible to minor group of patients because of poor reserved liver function associated with underlying liver disease and obstructive jaundice. Therefore many clinicians or centers still select locoregional therapy such as transarterial chemoembolization (TACE), radiation therapy (RT) etc. Stereotactic body radiation therapy (SBRT) is new technology providing very highly conformal ablative radiation dose for a small numbers (1-5 fractions) of large fraction size and is expected to salvage modality for HCC showed incomplete response of TACE due to vascularity or accessibility of feeding artery. Based on above suggestions, we herein offer our experience of a patient with partial remission of tumor by combination therapy of TACE, SBRT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic therapy (so called multidisciplinary approach), is necessary on how to manage HCC patients with bile duct invasion or sparse vascularity.
- A Case of Huge Hepatocellular Carcinoma with Complete Remission of Intrahepatic Tumor and Adrenal Gland Metastasis Treated with Combination Therapy of Transarterial Chemoembolization and Radiation Therapy and Sorafenib
-
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Joon Suk Kim, Sang Bu Ahn, Eun Kyeong Ji, Chul Won Choi, Gwang-Mo Yang
-
Journal of the Korean Liver Cancer Study Group. 2013;13(1):57-61. Published online February 28, 2013
-
DOI: https://doi.org/10.17998/jlc.13.1.57
-
-
Abstract
PDF
- Extrahepatic metastasis (EHM) associated with hepatocellular carcinoma (HCC) has been increasing due to prolonged
survival with recent advances in therapeutic approaches including locoregional therapy such as transarterial chemoemoblization
(TACE), radiofrequency ablation and radiation therapy (RT). Though many guidelines recommended systemic therapy such as
sorafenib in this situation, some clinicians or centers still select locoregional therapy because the survival improvement of 2 or 3
months by sorafenib is far from optimal. Moreover, some studies showed that complete and partial response of intrahepatic
tumors can result in significant improvement of patient survival even in situation of EHM. Based on above suggestions, we herein
offer our experience of a patient with complete remission of intrahepatic tumor and adrenal gland metastasis treated with
combination therapy of TACE and RT and sorafenib. Further study, maybe regarding a combination of locoregional and systemic
therapy (so called multidisciplinary approach), is necessary on how to manage HCC patients with EHM.
|